ET
ETLI.F Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF
- EUR
No recent price
- Total assets
- 36.5M
- Expense ratio
- 0.50%
- Dividend yield
- 0.92%
- 1-year return
- +25.48%
- Holdings
- 10
- Since
- 2018
Fund data as reported by the issuer, updated Nov 11, 2026. Total assets are in the fund's base currency.
What does ETLI.F invest in?
Tracks Morningstar Gbl Biotechnology NR USD- Mostly US stocks (74.4%)
- Largest sector: Healthcare (94.8%)
- Largest region: North America (69.1%)
- Top 3 holdings: 10.4% of the fund
Asset allocation
- US stocks 74.4%
- Non-US stocks 28.4%
- Cash 0.2%
Top holdings
- Genmab A/S 4.41%
- Xeris Pharmaceuticals Inc 3.07%
- United Therapeutics Corporation 2.92%
- Ligand Pharmaceuticals Incorporated 2.86%
- Xencor Inc 2.85%
Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF performance
Sharpe ratio 0.60- This year
- +1.17%
- 1 year
- +25.48%
- 3 years
- +3.47%
- 5 years
- +1.30%
Volatility 16.0% over 1 year and 15.2% over 3 years. Moderate, similar to a broad stock index.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
ETLI.F price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF top holdings
29.6% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Genmab A/S GMAB.CO | Healthcare | Denmark | 4.41% |
| Xeris Pharmaceuticals Inc XERS.US | Healthcare | United States | 3.07% |
| United Therapeutics Corporation UTHR.US | Healthcare | United States | 2.92% |
| Ligand Pharmaceuticals Incorporated LGND.US | Healthcare | United States | 2.86% |
| Xencor Inc XNCR.US | Healthcare | United States | 2.85% |
| Halozyme Therapeutics Inc HALO.US | Healthcare | United States | 2.78% |
| Biogen Inc BIIB.US | Healthcare | United States | 2.78% |
| AstraZeneca PLC AZN.LSE | Healthcare | United Kingdom | 2.76% |
| Basilea Pharmaceutica AG BSLN.SW | Healthcare | Switzerland | 2.66% |
| Eisai Co. Ltd. 4523.TSE | Healthcare | Japan | 2.54% |
ETLI.F sector exposure
- Healthcare94.8%
- Basic Materials1.9%
Share of the stocks in the fund.
ETLI.F regional exposure
- North America69.1%
- Europe Developed15.8%
- Japan9.0%
- Asia Developed2.6%
- Asia Emerging2.3%
Share of the stocks in the fund.
Company size
Average market cap 6.75B- Mega cap5.5%
- Big cap13.0%
- Medium cap33.1%
- Small cap27.6%
- Micro cap21.3%
Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF fund profile
- Fund name
- Legal & General UCITS ETF Plc - L&G Pharma Breakthrough UCITS ETF
- Ticker
- ETLI.F
- Exchange
- Frankfurt Exchange
- Issuer
- LGIM Managers (Europe) Limited
- Index tracked
- Morningstar Gbl Biotechnology NR USD
- Category
- Healthcare Equity
- Inception date
- Jan 18, 2018
- Trading currency
- EUR
- Expense ratio
- 0.50%